Growth Hormone plus Childhood Low-Dose Estrogen in Turner's Syndrome
Author(s) -
Judith L. Ross,
Charmian A. Quigley,
Dachuang Cao,
Penelope Feuillan,
Karen Kowal,
John J. Chipman,
Gordon B. Cutler
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1005669
Subject(s) - placebo , estrogen , medicine , turner syndrome , short stature , endocrinology , hormone , growth hormone deficiency , growth hormone , alternative medicine , pathology
Short stature and ovarian failure are characteristic features of Turner's syndrome. Although recombinant human growth hormone is commonly used to treat the short stature associated with this syndrome, a randomized, placebo-controlled trial is needed to document whether such treatment increases adult height. Furthermore, it is not known whether childhood estrogen replacement combined with growth hormone therapy provides additional benefit. We examined the independent and combined effects of growth hormone and early, ultra-low-dose estrogen on adult height in girls with Turner's syndrome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom